PUBLISHER: Grand View Research | PRODUCT CODE: 1375862
PUBLISHER: Grand View Research | PRODUCT CODE: 1375862
The global comprehensive metabolic panel testing market size is expected to reach USD 20.87 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 9.1% from 2023 to 2030. The market driven by an increasing global disease burden and the emergence of novel diagnostic products.
Rising prevalence of chronic diseases coupled with increasing need to curb healthcare expenditure are expected to boost the CMP testing market by increasing the demand for early disease diagnosis and regular monitoring. Introduction of technologically advanced products, such as biochips, microarrays, and companion diagnostics, has driven the necessity for early detection of anomalies. CMP testing offers a cost-effective and time-saving method for evaluating 14 analytes for identification, diagnosis, or monitoring of several diseases.
Rising consumer awareness regarding healthcare is one of the major factors anticipated to drive the market for CMP testing. Many organizations worldwide are working toward increasing awareness pertaining to diseases, available treatment options, and benefits of early diagnosis and precautions. For instance, the International Diabetes Foundation and the American Diabetes Association are some of the key organizations that emphasize the urgent need for diagnosing and monitoring diabetes through several awareness campaigns and other modes of advertisement.
The buying behavior of consumers is moderately complex in the comprehensive metabolic panel testing market, due to subtle differences in product prices. The products offered by various market players have been strategically priced to increase competitive rivalry. As the market becomes increasingly competitive, consumer needs are anticipated to reach at an all-time high for improved diagnostics - in terms of safety, efficacy, sensitivity, and specificity.
The medical diagnostics landscape has undergone a paradigm shift over the last few years, driven by the launch of improved diagnostic products and introduction of biomarkers. However, recurrence and disease progression remain high, especially among geriatric patients. Strong unmet needs present a key opportunity to develop breakthrough first-in-class diagnostics in the CMP testing space.